Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.32
CRMD's Cash to Debt is ranked higher than
50% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. CRMD: 0.32 )
CRMD' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: 0.32

Z-Score: 17.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROA (%) -293.24
CRMD's ROA (%) is ranked lower than
53% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. CRMD: -293.24 )
CRMD' s 10-Year ROA (%) Range
Min: -364.82   Max: -123.25
Current: -293.24

-364.82
-123.25
ROC (Joel Greenblatt) (%) -60000.00
CRMD's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. CRMD: -60000.00 )
CRMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -60058.33   Max: -25229.17
Current: -60000

-60058.33
-25229.17
» CRMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

CRMD Guru Trades in Q1 2013

Paul Singer 781,440 sh (unchged)
» More
Q2 2013

CRMD Guru Trades in Q2 2013

Paul Singer 781,440 sh (unchged)
» More
Q3 2013

CRMD Guru Trades in Q3 2013

Paul Singer 781,440 sh (unchged)
» More
Q4 2013

CRMD Guru Trades in Q4 2013

Paul Singer 781,440 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRMD



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S No Debt
CRMD's P/S is ranked lower than
96% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. CRMD: No Debt )
CRMD' s 10-Year P/S Range
Min: 0   Max: 10670.7
Current: No Debt

0
10670.7
EV-to-EBIT 250.00
CRMD's EV-to-EBIT is ranked lower than
84% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. CRMD: 250.00 )
CRMD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 250

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Cormedix, Inc. was organized as a Delaware corporation on July 28, 2006 under the name Picton Holding Company, Inc. and changed it to CorMedix Inc. on January 18, 2007. The Company develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Its principal product under development includes CRMD003, an antimicrobial/anticoagulant solution applied in the prevention of catheter related bloodstream infections and maintenance of catheter patency in central venous catheters used for vascular access in hemodialysis patients. Its products also include CRMD004, a pressure sensitive gel that is in pre-clinical Phase.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide